To analyse whether calpastatin protection against cardiovascular remodelling or even kidney lesions would result from changes in hemodynamics, a specific set of invasive experiments has been performed in one-year old CalpTG and WT mice (Fig. 5). We did not observe any change in arterial blood pressure, renal blood flow or measured glomerular filtration rate at one year (Fig. 5A–C). One year-old CalpTG mice heart weight was 135 ± 9 mg whereas WT mice heart weight was 159 ± 9 mg (n = 7/group, p = 0.05), suggesting that cardiovascular remodelling was ongoing at this time (Fig. 5D).Figure 5Calpastatin overexpression does not impact hemodynamic or renal blood flow. At one year, blood pressure, renal blood flow and glomerular filtration rate (GFR) were similar in CalpTG (TG) and WT mice, evidencing that calpastatin does not protect kidney through hemodynamic improvement (A–C, n = 6–10/group). Although hemodynamic features were similar, there was a trend toward lower heart mass in CalpTG (TG) mice at one year (D, p = 0.05, n = 7/group).